{"transactions":[{"id":960882,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":25480,"kind":"person","name":"Lazar David E.","position":1,"cik":"0001932843","reported_name":"Lazar David E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Convertible Loan","published_at":"2025-12-22T22:18:14.000Z","date":"2025-12-18","kind":"other","planned":false,"acquired":false,"shares":368614,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On November 9, 2025, the Reporting Person, as \"Lender\", entered into a Convertible Loan Agreement (the \"Agreement\") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the \"Conversion Price\" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On November 9, 2025, the Reporting Person, as \"Lender\", entered into a Convertible Loan Agreement (the \"Agreement\") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the \"Conversion Price\" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash."}],"balance_after":0,"derivative":{"exercise_price":1.017,"exercise_date":"2025-11-09","underlying":"Common Stock","underlying_shares":368614},"source":{"system":"sec-edgar","filing":"0000921895-25-003381","document":"form412227021_12222025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000092189525003381/form412227021_12222025.xml","form_type":"4"}},{"id":986911,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":25480,"kind":"person","name":"Lazar David E.","position":1,"cik":"0001932843","reported_name":"Lazar David E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series AA Convertible Preferred Stock","published_at":"2025-11-26T20:03:05.000Z","date":"2025-11-24","kind":"grant","planned":false,"acquired":true,"shares":900000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On November 24, 2025, David E. Lazar (the \"Reporting Person\") and KALA BIO, Inc. (the \"Company\") entered into a securies purchase agreement (the \"Purchase Agreement\") pursuant to which the Reporting Person acquired an aggregate of 900,000 shares of the Company's Series AA Convertible Non-Redeemable Preferred Stock (the \"Series AA Preferred Stock\") at a price of $2.00 per share, for a total purchase price of $1,800,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing, an aggregate of 2,100,000 shares of the Company's Series AAA Convertible Non-Redeemable Preferred Stock (the \"Series AAA Preferred Stock\", and together with the Series AA Preferred Stock, the \"Preferred Stock\") at a price of $2.00 per share, for an additional purchase price of $4,200,000."},{"field":"security","element":"securityTitle","label":"F3","text":"Each share of Series AA Preferred Stock will be convertible into 55 shares of the Company's common stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock will be convertible into 420 shares of the Company's common stock at any time, subject to certain ownership limitations. No shares of Preferred Stock will be convertible until the Company's stockholders approve a) an increase in the Company's authorized capital to enable the Company to issue all of the shares of common stock that are issuable upon the conversion of the Preferred Stock and b) the conversion of the Preferred Stock into shares of common stock in accordance with the listing rules of The Nasdaq Stock Market, LLC (the \"Stockholder Approval\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Following receipt by the Company of the Stockholder Approval, the shares of Series AA Preferred Stock will be convertible at the option of the Reporting Person for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 24, 2025, David E. Lazar (the \"Reporting Person\") and KALA BIO, Inc. (the \"Company\") entered into a securies purchase agreement (the \"Purchase Agreement\") pursuant to which the Reporting Person acquired an aggregate of 900,000 shares of the Company's Series AA Convertible Non-Redeemable Preferred Stock (the \"Series AA Preferred Stock\") at a price of $2.00 per share, for a total purchase price of $1,800,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing, an aggregate of 2,100,000 shares of the Company's Series AAA Convertible Non-Redeemable Preferred Stock (the \"Series AAA Preferred Stock\", and together with the Series AA Preferred Stock, the \"Preferred Stock\") at a price of $2.00 per share, for an additional purchase price of $4,200,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series AA Preferred Stock will be convertible into 55 shares of the Company's common stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock will be convertible into 420 shares of the Company's common stock at any time, subject to certain ownership limitations. No shares of Preferred Stock will be convertible until the Company's stockholders approve a) an increase in the Company's authorized capital to enable the Company to issue all of the shares of common stock that are issuable upon the conversion of the Preferred Stock and b) the conversion of the Preferred Stock into shares of common stock in accordance with the listing rules of The Nasdaq Stock Market, LLC (the \"Stockholder Approval\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series AA Preferred Stock is perpetual and therefore has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each share of Series AA Preferred Stock will be convertible into 55 shares of the Company's common stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock will be convertible into 420 shares of the Company's common stock at any time, subject to certain ownership limitations. No shares of Preferred Stock will be convertible until the Company's stockholders approve a) an increase in the Company's authorized capital to enable the Company to issue all of the shares of common stock that are issuable upon the conversion of the Preferred Stock and b) the conversion of the Preferred Stock into shares of common stock in accordance with the listing rules of The Nasdaq Stock Market, LLC (the \"Stockholder Approval\")."}],"balance_after":900000,"derivative":{"underlying":"Common Stock","underlying_shares":49500000},"source":{"system":"sec-edgar","filing":"0000921895-25-003208","document":"form412227001_11262025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000092189525003208/form412227001_11262025.xml","form_type":"4"}},{"id":1013799,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-25T00:00:13.000Z","date":"2025-10-23","kind":"sale","planned":false,"acquired":false,"shares":154894,"price":0.81,"value":125464.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 103,540 unvested RSUs."}],"balance_after":103540,"source":{"system":"sec-edgar","filing":"0001415537-25-000004","document":"form4-10242025_081010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141553725000004/form4-10242025_081010.xml","form_type":"4"}},{"id":1013798,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-25T00:00:09.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":47768,"price":0.83,"value":39647.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 35,732 unvested RSUs."}],"balance_after":35932,"source":{"system":"sec-edgar","filing":"0001605767-25-000004","document":"form4-10242025_081006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000160576725000004/form4-10242025_081006.xml","form_type":"4"}},{"id":1013797,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-10-25T00:00:07.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":46748,"price":0.83,"value":38800.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 35,952 unvested RSUs."}],"balance_after":35952,"source":{"system":"sec-edgar","filing":"0001298079-25-000003","document":"form4-10242025_081004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000129807925000003/form4-10242025_081004.xml","form_type":"4"}},{"id":1013795,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-10-25T00:00:05.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":20806,"price":0.83,"value":17268.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,878 unvested RSUs."}],"balance_after":41760,"source":{"system":"sec-edgar","filing":"0001893729-25-000003","document":"form4-10242025_081001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000189372925000003/form4-10242025_081001.xml","form_type":"4"}},{"id":1013834,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-24T20:00:12.000Z","date":"2025-10-23","kind":"sale","planned":false,"acquired":false,"shares":967,"price":0.82,"value":792.94,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,906 unvested RSUs."}],"balance_after":28906,"source":{"system":"sec-edgar","filing":"0001710969-25-000003","document":"form4-10242025_081007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000171096925000003/form4-10242025_081007.xml","form_type":"4"}},{"id":1013833,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-24T20:00:12.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":32230,"price":0.83,"value":26750.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,906 unvested RSUs."}],"balance_after":29873,"source":{"system":"sec-edgar","filing":"0001710969-25-000003","document":"form4-10242025_081007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000171096925000003/form4-10242025_081007.xml","form_type":"4"}},{"id":1028127,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common Stock","published_at":"2025-10-02T20:47:53.000Z","date":"2025-10-01","kind":"sale","planned":false,"acquired":false,"shares":462967,"price":1.3838,"value":640653.7346,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $1.27 to $1.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J.Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":425006,"source":{"system":"sec-edgar","filing":"0001193125-25-228536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525228536/ownership.xml","form_type":"4"}},{"id":1028126,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common Stock","published_at":"2025-10-02T20:47:53.000Z","date":"2025-10-01","kind":"sale","planned":false,"acquired":false,"shares":50640,"price":1.3838,"value":70075.632,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $1.27 to $1.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":46480,"source":{"system":"sec-edgar","filing":"0001193125-25-228536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525228536/ownership.xml","form_type":"4"}},{"id":1028125,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common Stock","published_at":"2025-10-02T20:47:53.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":195425,"price":1.5959,"value":311878.7575,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of KALA BIO, Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $1.50 to $1.84, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J.Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":887973,"source":{"system":"sec-edgar","filing":"0001193125-25-228536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525228536/ownership.xml","form_type":"4"}},{"id":1028124,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common Stock","published_at":"2025-10-02T20:47:53.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":21376,"price":1.5959,"value":34113.9584,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of KALA BIO, Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $1.50 to $1.84, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":97120,"source":{"system":"sec-edgar","filing":"0001193125-25-228536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525228536/ownership.xml","form_type":"4"}},{"id":1051397,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2025-09-02T20:08:52.000Z","date":"2025-08-29","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 29, 2025 and vests over four years beginning on the vesting commencement date of August 29, 2025, with 1/48th of the shares underlying the option vesting at the end of each successive one-month period thereafter until August 29, 2029, subject to the Reporting Person's continued service."}],"balance_after":180000,"derivative":{"exercise_price":11.22,"expiration_date":"2035-08-28","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001104659-25-086367","document":"tm2524823-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925086367/tm2524823-1_4seq1.xml","form_type":"4"}},{"id":1101040,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-06-27T00:00:19.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":4511,"price":4.01,"value":18089.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 28,878 unvested RSUs."}],"balance_after":62566,"source":{"system":"sec-edgar","filing":"0001415889-25-018321","document":"form4-06262025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925018321/form4-06262025_080609.xml","form_type":"4"}},{"id":1101036,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-06-27T00:00:14.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":4058,"price":4.01,"value":16272.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 35,732 unvested RSUs."}],"balance_after":83699,"source":{"system":"sec-edgar","filing":"0001415889-25-018319","document":"form4-06262025_080605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925018319/form4-06262025_080605.xml","form_type":"4"}},{"id":1101035,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-06-27T00:00:12.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":5251,"price":4.01,"value":21056.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 35,952 unvested RSUs."}],"balance_after":82698,"source":{"system":"sec-edgar","filing":"0001415889-25-018318","document":"form4-06262025_080603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925018318/form4-06262025_080603.xml","form_type":"4"}},{"id":1101034,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T00:00:11.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":13227,"price":4.01,"value":53040.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 103,540 unvested RSUs."}],"balance_after":258433,"source":{"system":"sec-edgar","filing":"0001415889-25-018317","document":"form4-06262025_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925018317/form4-06262025_080601.xml","form_type":"4"}},{"id":1101076,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-06-26T20:00:16.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":3631,"price":4.01,"value":14560.31,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 28,906 unvested RSUs."}],"balance_after":62100,"source":{"system":"sec-edgar","filing":"0001415889-25-018320","document":"form4-06262025_080607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925018320/form4-06262025_080607.xml","form_type":"4"}},{"id":1107900,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78386,"kind":"person","name":"Rosen Howard B","position":1,"cik":"0001307068","reported_name":"Rosen Howard B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T00:00:19.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":5450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."}],"balance_after":5450,"derivative":{"exercise_price":4.3,"expiration_date":"2035-06-14","underlying":"Common Stock","underlying_shares":5450},"source":{"system":"sec-edgar","filing":"0001415889-25-017616","document":"form4-06172025_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017616/form4-06172025_080614.xml","form_type":"4"}},{"id":1107899,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78386,"kind":"person","name":"Rosen Howard B","position":1,"cik":"0001307068","reported_name":"Rosen Howard B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T00:00:19.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":2450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,776 unvested RSUs."}],"balance_after":16240,"source":{"system":"sec-edgar","filing":"0001415889-25-017616","document":"form4-06172025_080614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017616/form4-06172025_080614.xml","form_type":"4"}},{"id":1107898,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T00:00:15.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":5450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."}],"balance_after":5450,"derivative":{"exercise_price":4.3,"expiration_date":"2035-06-14","underlying":"Common Stock","underlying_shares":5450},"source":{"system":"sec-edgar","filing":"0001415889-25-017615","document":"form4-06172025_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017615/form4-06172025_080611.xml","form_type":"4"}},{"id":1107897,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T00:00:15.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":2450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 156,492 unvested RSUs."}],"balance_after":271660,"source":{"system":"sec-edgar","filing":"0001415889-25-017615","document":"form4-06172025_080611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017615/form4-06172025_080611.xml","form_type":"4"}},{"id":1107896,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T00:00:13.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":5450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."}],"balance_after":5450,"derivative":{"exercise_price":4.3,"expiration_date":"2035-06-14","underlying":"Common Stock","underlying_shares":5450},"source":{"system":"sec-edgar","filing":"0001415889-25-017614","document":"form4-06172025_080609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017614/form4-06172025_080609.xml","form_type":"4"}},{"id":1107895,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T00:00:13.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":2450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,134 unvested RSUs."}],"balance_after":10242,"source":{"system":"sec-edgar","filing":"0001415889-25-017614","document":"form4-06172025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017614/form4-06172025_080609.xml","form_type":"4"}},{"id":1107894,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":71639,"kind":"person","name":"PERRY GREGORY D","position":1,"cik":"0001236371","reported_name":"PERRY GREGORY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T00:00:10.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":5450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."}],"balance_after":5450,"derivative":{"exercise_price":4.3,"expiration_date":"2035-06-14","underlying":"Common Stock","underlying_shares":5450},"source":{"system":"sec-edgar","filing":"0001415889-25-017613","document":"form4-06172025_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017613/form4-06172025_080606.xml","form_type":"4"}},{"id":1107893,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":71639,"kind":"person","name":"PERRY GREGORY D","position":1,"cik":"0001236371","reported_name":"PERRY GREGORY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T00:00:10.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":2450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,355 unvested RSUs."}],"balance_after":13344,"source":{"system":"sec-edgar","filing":"0001415889-25-017613","document":"form4-06172025_080606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017613/form4-06172025_080606.xml","form_type":"4"}},{"id":1107892,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":40433,"kind":"person","name":"KOVEN ANDREW I","position":1,"cik":"0001258673","reported_name":"KOVEN ANDREW I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T00:00:05.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":6850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."}],"balance_after":6850,"derivative":{"exercise_price":4.3,"expiration_date":"2035-06-14","underlying":"Common Stock","underlying_shares":6850},"source":{"system":"sec-edgar","filing":"0001415889-25-017611","document":"form4-06172025_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017611/form4-06172025_080601.xml","form_type":"4"}},{"id":1107891,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":40433,"kind":"person","name":"KOVEN ANDREW I","position":1,"cik":"0001258673","reported_name":"KOVEN ANDREW I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T00:00:05.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":3050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 8,061 unvested RSUs."}],"balance_after":16972,"source":{"system":"sec-edgar","filing":"0001415889-25-017611","document":"form4-06172025_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925017611/form4-06172025_080601.xml","form_type":"4"}},{"id":1107922,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78387,"kind":"person","name":"Myers C. Daniel","position":1,"cik":"0001489533","reported_name":"Myers C. Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:00:07.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":5450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."}],"balance_after":5450,"derivative":{"exercise_price":4.3,"expiration_date":"2035-06-14","underlying":"Common Stock","underlying_shares":5450},"source":{"system":"sec-edgar","filing":"0001415889-25-017612","document":"form4-06172025_080603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1489533/000141588925017612/form4-06172025_080603.xml","form_type":"4"}},{"id":1107921,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78387,"kind":"person","name":"Myers C. Daniel","position":1,"cik":"0001489533","reported_name":"Myers C. Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T20:00:07.000Z","date":"2025-06-15","kind":"grant","planned":false,"acquired":true,"shares":2450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,973 unvested RSUs."}],"balance_after":10374,"source":{"system":"sec-edgar","filing":"0001415889-25-017612","document":"form4-06172025_080603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1489533/000141588925017612/form4-06172025_080603.xml","form_type":"4"}},{"id":1121250,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T01:44:38.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":10866,"price":3.74,"value":40638.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"This amendment is being filed solely to correct the nature of the transaction reported in Column 4 of Table I of the Form 4 filed by the Reporting Person on June 4, 2025. As reported in this amendment, such transaction resulted in a \"disposition\" of common stock by the Reporting Person and not an \"acquisition\" as previously reported."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 154,042 unvested RSUs."}],"balance_after":269210,"source":{"system":"sec-edgar","filing":"0001104659-25-056986","document":"tm2517328-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925056986/tm2517328-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-06-04"}},{"id":1122815,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-06-05T00:00:16.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":730,"price":3.74,"value":2730.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 41,159 unvested RSUs."}],"balance_after":67077,"source":{"system":"sec-edgar","filing":"0001415889-25-015681","document":"form4-06042025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925015681/form4-06042025_080609.xml","form_type":"4"}},{"id":1122814,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-06-05T00:00:14.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":3390,"price":3.74,"value":12678.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 51,963 unvested RSUs."}],"balance_after":87757,"source":{"system":"sec-edgar","filing":"0001415889-25-015679","document":"form4-06042025_080606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925015679/form4-06042025_080606.xml","form_type":"4"}},{"id":1122813,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-06-05T00:00:12.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":3687,"price":3.74,"value":13789.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 52,402 unvested RSUs."}],"balance_after":87949,"source":{"system":"sec-edgar","filing":"0001415889-25-015678","document":"form4-06042025_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925015678/form4-06042025_080604.xml","form_type":"4"}},{"id":1122812,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T00:00:09.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":true,"shares":10866,"price":3.74,"value":40638.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 154,042 unvested RSUs."}],"balance_after":269210,"source":{"system":"sec-edgar","filing":"0001415889-25-015677","document":"form4-06042025_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925015677/form4-06042025_080601.xml","form_type":"4"}},{"id":1122961,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-06-04T20:00:15.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":2850,"price":3.74,"value":10659.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 40,953 unvested RSUs."}],"balance_after":65731,"source":{"system":"sec-edgar","filing":"0001415889-25-015680","document":"form4-06042025_080607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925015680/form4-06042025_080607.xml","form_type":"4"}},{"id":1214959,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-11T00:00:08.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":45200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 7, 2025 and vests as to 1/12th of the shares underlying the option at the end of each successive one-month period over a one-year period following February 11, 2025, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":45200,"derivative":{"exercise_price":7.05,"expiration_date":"2035-03-06","underlying":"Common Stock","underlying_shares":45200},"source":{"system":"sec-edgar","filing":"0001415889-25-007598","document":"form4-03102025_080302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925007598/form4-03102025_080302.xml","form_type":"4"}},{"id":1307947,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-08T01:14:26.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":45200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":45200,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":45200},"source":{"system":"sec-edgar","filing":"0001415889-25-001063","document":"form4-01082025_010122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001063/form4-01082025_010122.xml","form_type":"4"}},{"id":1307946,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:14:26.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":2021,"price":7.63,"value":15420.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 42,966 unvested RSUs."}],"balance_after":67807,"source":{"system":"sec-edgar","filing":"0001415889-25-001063","document":"form4-01082025_010122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001063/form4-01082025_010122.xml","form_type":"4"}},{"id":1307945,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:14:26.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2025, as to 1/3 of the shares underlying the RSUs on January 6, 2026 and as to the final 1/3 of shares underlying the RSUs on January 6, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 42,966 unvested RSUs."}],"balance_after":69828,"source":{"system":"sec-edgar","filing":"0001415889-25-001063","document":"form4-01082025_010122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001063/form4-01082025_010122.xml","form_type":"4"}},{"id":1307944,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-08T01:14:03.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":45200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":45200,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":45200},"source":{"system":"sec-edgar","filing":"0001415889-25-001062","document":"form4-01082025_010100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001062/form4-01082025_010100.xml","form_type":"4"}},{"id":1307943,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-01-08T01:14:03.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":1993,"price":7.63,"value":15206.59,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Includes 64,324 unvested RSUs."}],"source":{"system":"sec-edgar","filing":"0001415889-25-001062","document":"form4-01082025_010100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001062/form4-01082025_010100.xml","form_type":"4"}},{"id":1307942,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-01-08T01:14:03.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Includes 64,324 unvested RSUs."}],"source":{"system":"sec-edgar","filing":"0001415889-25-001062","document":"form4-01082025_010100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001062/form4-01082025_010100.xml","form_type":"4"}},{"id":1307941,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-08T01:13:39.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":45200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":45200,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":45200},"source":{"system":"sec-edgar","filing":"0001415889-25-001061","document":"form4-01082025_010135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001061/form4-01082025_010135.xml","form_type":"4"}},{"id":1307940,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-01-08T01:13:39.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":2446,"price":7.63,"value":18662.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 62,961 unvested RSUs."}],"balance_after":92418,"source":{"system":"sec-edgar","filing":"0001415889-25-001061","document":"form4-01082025_010135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001061/form4-01082025_010135.xml","form_type":"4"}},{"id":1307939,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-01-08T01:13:39.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 62,961 unvested RSUs."}],"balance_after":94864,"source":{"system":"sec-edgar","filing":"0001415889-25-001061","document":"form4-01082025_010135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001061/form4-01082025_010135.xml","form_type":"4"}},{"id":1307938,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-08T01:12:59.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":99500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":99500,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":99500},"source":{"system":"sec-edgar","filing":"0001415889-25-001060","document":"form4-01082025_010156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001060/form4-01082025_010156.xml","form_type":"4"}},{"id":1307937,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:12:59.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":5779,"price":7.63,"value":44093.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 194,739 unvested RSUs."}],"balance_after":280076,"source":{"system":"sec-edgar","filing":"0001415889-25-001060","document":"form4-01082025_010156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001060/form4-01082025_010156.xml","form_type":"4"}},{"id":1307936,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:12:59.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 194,739 unvested RSUs."}],"balance_after":285855,"source":{"system":"sec-edgar","filing":"0001415889-25-001060","document":"form4-01082025_010156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001060/form4-01082025_010156.xml","form_type":"4"}},{"id":1308109,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T20:12:29.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":45200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":45200,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":45200},"source":{"system":"sec-edgar","filing":"0001415889-25-001059","document":"form4-01082025_010125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925001059/form4-01082025_010125.xml","form_type":"4"}},{"id":1308108,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-07T20:12:29.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":1706,"price":7.63,"value":13016.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,523 unvested RSUs."}],"balance_after":68581,"source":{"system":"sec-edgar","filing":"0001415889-25-001059","document":"form4-01082025_010125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925001059/form4-01082025_010125.xml","form_type":"4"}},{"id":1308107,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-07T20:12:29.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,523 unvested RSUs."}],"balance_after":70287,"source":{"system":"sec-edgar","filing":"0001415889-25-001059","document":"form4-01082025_010125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925001059/form4-01082025_010125.xml","form_type":"4"}},{"id":1320053,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-31T21:00:18.000Z","date":"2024-12-30","kind":"purchase","planned":false,"acquired":true,"shares":279939,"price":6.44,"value":1802807.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased 30,620 and 279,939 shares of common stock (\"Common Stock\") of KALA BIO, Inc. (the \"Issuer\"), respectively, for $6.44 per share pursuant to a private placement with the Issuer that closed on December 31, 2024 (the \"Private Placement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J.Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":1083398,"source":{"system":"sec-edgar","filing":"0000950170-24-141592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024141592/ownership.xml","form_type":"4"}},{"id":1320052,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-31T21:00:18.000Z","date":"2024-12-30","kind":"purchase","planned":false,"acquired":true,"shares":30620,"price":6.44,"value":197192.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased 30,620 and 279,939 shares of common stock (\"Common Stock\") of KALA BIO, Inc. (the \"Issuer\"), respectively, for $6.44 per share pursuant to a private placement with the Issuer that closed on December 31, 2024 (the \"Private Placement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":118496,"source":{"system":"sec-edgar","filing":"0000950170-24-141592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024141592/ownership.xml","form_type":"4"}},{"id":1468097,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-06-28T00:00:14.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":4653,"price":4.75,"value":22101.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 60,656 unvested RSUs."}],"balance_after":83040,"source":{"system":"sec-edgar","filing":"0001415889-24-018377","document":"form4-06272024_080611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924018377/form4-06272024_080611.xml","form_type":"4"}},{"id":1468096,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T00:00:11.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":5158,"price":4.75,"value":24500.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 37,574 unvested RSUs."}],"balance_after":59728,"source":{"system":"sec-edgar","filing":"0001415889-24-018376","document":"form4-06272024_080608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924018376/form4-06272024_080608.xml","form_type":"4"}},{"id":1468095,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T00:00:07.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":15168,"price":4.75,"value":72048.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 191,304 unvested RSUs."}],"balance_after":263755,"source":{"system":"sec-edgar","filing":"0001415889-24-018374","document":"form4-06272024_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924018374/form4-06272024_080604.xml","form_type":"4"}},{"id":1468094,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-06-28T00:00:05.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":5489,"price":4.75,"value":26072.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 59,293 unvested RSUs."}],"balance_after":83982,"source":{"system":"sec-edgar","filing":"0001415889-24-018373","document":"form4-06272024_080602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924018373/form4-06272024_080602.xml","form_type":"4"}},{"id":1468164,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-27T20:00:09.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":4163,"price":4.75,"value":19774.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 44,131 unvested RSUs."}],"balance_after":60187,"source":{"system":"sec-edgar","filing":"0001415889-24-018375","document":"form4-06272024_080606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924018375/form4-06272024_080606.xml","form_type":"4"}},{"id":1482012,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78386,"kind":"person","name":"Rosen Howard B","position":1,"cik":"0001307068","reported_name":"Rosen Howard B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-13T00:00:17.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."}],"balance_after":3150,"derivative":{"exercise_price":6.18,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001415889-24-016574","document":"form4-06122024_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016574/form4-06122024_080614.xml","form_type":"4"}},{"id":1482011,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78386,"kind":"person","name":"Rosen Howard B","position":1,"cik":"0001307068","reported_name":"Rosen Howard B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T00:00:17.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,040 unvested RSUs."}],"balance_after":13887,"source":{"system":"sec-edgar","filing":"0001415889-24-016574","document":"form4-06122024_080614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016574/form4-06122024_080614.xml","form_type":"4"}},{"id":1482010,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-13T00:00:15.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."}],"balance_after":3150,"derivative":{"exercise_price":6.18,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001415889-24-016573","document":"form4-06122024_080612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016573/form4-06122024_080612.xml","form_type":"4"}},{"id":1482009,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T00:00:15.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,692 unvested RSUs."}],"balance_after":7792,"source":{"system":"sec-edgar","filing":"0001415889-24-016573","document":"form4-06122024_080612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016573/form4-06122024_080612.xml","form_type":"4"}},{"id":1482008,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":71639,"kind":"person","name":"PERRY GREGORY D","position":1,"cik":"0001236371","reported_name":"PERRY GREGORY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-13T00:00:13.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."}],"balance_after":3150,"derivative":{"exercise_price":6.18,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001415889-24-016572","document":"form4-06122024_080609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016572/form4-06122024_080609.xml","form_type":"4"}},{"id":1482007,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":71639,"kind":"person","name":"PERRY GREGORY D","position":1,"cik":"0001236371","reported_name":"PERRY GREGORY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T00:00:13.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 8,525 unvested RSUs."}],"balance_after":10894,"source":{"system":"sec-edgar","filing":"0001415889-24-016572","document":"form4-06122024_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016572/form4-06122024_080609.xml","form_type":"4"}},{"id":1482006,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":40433,"kind":"person","name":"KOVEN ANDREW I","position":1,"cik":"0001258673","reported_name":"KOVEN ANDREW I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-13T00:00:08.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."}],"balance_after":3900,"derivative":{"exercise_price":6.18,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001415889-24-016570","document":"form4-06122024_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016570/form4-06122024_080605.xml","form_type":"4"}},{"id":1482005,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":40433,"kind":"person","name":"KOVEN ANDREW I","position":1,"cik":"0001258673","reported_name":"KOVEN ANDREW I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T00:00:08.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,864 unvested RSUs."}],"balance_after":13922,"source":{"system":"sec-edgar","filing":"0001415889-24-016570","document":"form4-06122024_080605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016570/form4-06122024_080605.xml","form_type":"4"}},{"id":1482004,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-13T00:00:06.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."}],"balance_after":3150,"derivative":{"exercise_price":6.18,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001415889-24-016569","document":"form4-06122024_080602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016569/form4-06122024_080602.xml","form_type":"4"}},{"id":1482003,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T00:00:06.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,615 unvested RSUs."}],"balance_after":13091,"source":{"system":"sec-edgar","filing":"0001415889-24-016569","document":"form4-06122024_080602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016569/form4-06122024_080602.xml","form_type":"4"}},{"id":1482025,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78387,"kind":"person","name":"Myers C. Daniel","position":1,"cik":"0001489533","reported_name":"Myers C. Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T20:00:11.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."}],"balance_after":3150,"derivative":{"exercise_price":6.18,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001415889-24-016571","document":"form4-06122024_080607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1489533/000141588924016571/form4-06122024_080607.xml","form_type":"4"}},{"id":1482024,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78387,"kind":"person","name":"Myers C. Daniel","position":1,"cik":"0001489533","reported_name":"Myers C. Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-12T20:00:11.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,603 unvested RSUs."}],"balance_after":7924,"source":{"system":"sec-edgar","filing":"0001415889-24-016571","document":"form4-06122024_080607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1489533/000141588924016571/form4-06122024_080607.xml","form_type":"4"}},{"id":1495047,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-06-04T00:00:17.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":2093,"price":6.09,"value":12746.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 76,887 unvested RSUs."}],"balance_after":87693,"source":{"system":"sec-edgar","filing":"0001415889-24-015226","document":"form4-06032024_080613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924015226/form4-06032024_080613.xml","form_type":"4"}},{"id":1495045,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-06-04T00:00:14.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":231,"price":6.09,"value":1406.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 49,855 unvested RSUs."}],"balance_after":64886,"source":{"system":"sec-edgar","filing":"0001415889-24-015225","document":"form4-06032024_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924015225/form4-06032024_080610.xml","form_type":"4"}},{"id":1495046,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-06-04T00:00:09.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":2002,"price":6.09,"value":12192.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 75,743 unvested RSUs."}],"balance_after":89471,"source":{"system":"sec-edgar","filing":"0001415889-24-015223","document":"form4-06032024_080605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924015223/form4-06032024_080605.xml","form_type":"4"}},{"id":1495044,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-06-04T00:00:06.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":7392,"price":6.09,"value":45017.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 244,256 unvested RSUs."}],"balance_after":278923,"source":{"system":"sec-edgar","filing":"0001415889-24-015222","document":"form4-06032024_080602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924015222/form4-06032024_080602.xml","form_type":"4"}},{"id":1495204,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-03T20:00:12.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":1786,"price":6.09,"value":10876.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 56,177 unvested RSUs."}],"balance_after":64350,"source":{"system":"sec-edgar","filing":"0001415889-24-015224","document":"form4-06032024_080608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924015224/form4-06032024_080608.xml","form_type":"4"}},{"id":1685446,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:06:08.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":20500,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001415889-24-000771","document":"form4-01052024_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000771/form4-01052024_090101.xml","form_type":"4"}},{"id":1685445,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:06:08.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1385,"price":6.73,"value":9321.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 50,446 unvested RSUs."}],"balance_after":65117,"source":{"system":"sec-edgar","filing":"0001415889-24-000771","document":"form4-01052024_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000771/form4-01052024_090101.xml","form_type":"4"}},{"id":1685444,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:06:08.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 53,620 unvested RSUs."}],"balance_after":66502,"source":{"system":"sec-edgar","filing":"0001415889-24-000771","document":"form4-01052024_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000771/form4-01052024_090101.xml","form_type":"4"}},{"id":1685443,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:05:36.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":29300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":29300,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":29300},"source":{"system":"sec-edgar","filing":"0001415889-24-000770","document":"form4-01052024_090119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000770/form4-01052024_090119.xml","form_type":"4"}},{"id":1685442,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-01-05T21:05:36.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1617,"price":6.74,"value":10898.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 82,306 unvested RSUs."}],"balance_after":91473,"source":{"system":"sec-edgar","filing":"0001415889-24-000770","document":"form4-01052024_090119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000770/form4-01052024_090119.xml","form_type":"4"}},{"id":1685441,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73969,"kind":"person","name":"Brazzell Romulus K","position":1,"cik":"0001298079","reported_name":"Brazzell Romulus K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-01-05T21:05:36.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 86,756 unvested RSUs and 782 shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on July 3, 2023."}],"balance_after":93090,"source":{"system":"sec-edgar","filing":"0001415889-24-000770","document":"form4-01052024_090119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000770/form4-01052024_090119.xml","form_type":"4"}},{"id":1685440,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:04:45.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":64500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":64500,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":64500},"source":{"system":"sec-edgar","filing":"0001415889-24-000769","document":"form4-01052024_090140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000769/form4-01052024_090140.xml","form_type":"4"}},{"id":1685439,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:04:45.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":4539,"price":6.73,"value":30547.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 272,690 unvested RSUs."}],"balance_after":286315,"source":{"system":"sec-edgar","filing":"0001415889-24-000769","document":"form4-01052024_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000769/form4-01052024_090140.xml","form_type":"4"}},{"id":1685438,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":29290,"kind":"person","name":"Iwicki Mark T","position":1,"cik":"0001415537","reported_name":"Iwicki Mark T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:04:45.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":14300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 287,095 unvested RSUs."}],"balance_after":290854,"source":{"system":"sec-edgar","filing":"0001415889-24-000769","document":"form4-01052024_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000769/form4-01052024_090140.xml","form_type":"4"}},{"id":1685437,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:03:18.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":29300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":29300,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":29300},"source":{"system":"sec-edgar","filing":"0001415889-24-000766","document":"form4-01052024_090104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000766/form4-01052024_090104.xml","form_type":"4"}},{"id":1685436,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-01-05T21:03:18.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1405,"price":6.74,"value":9469.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F5","text":"Includes 84,890 unvested RSUs."}],"source":{"system":"sec-edgar","filing":"0001415889-24-000766","document":"form4-01052024_090104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000766/form4-01052024_090104.xml","form_type":"4"}},{"id":1685435,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73970,"kind":"person","name":"Bazemore Todd","position":1,"cik":"0001605767","reported_name":"Bazemore Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-01-05T21:03:18.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Includes 89,340 unvested RSUs."}],"source":{"system":"sec-edgar","filing":"0001415889-24-000766","document":"form4-01052024_090104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000766/form4-01052024_090104.xml","form_type":"4"}},{"id":1685477,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":95409,"kind":"person","name":"Trachtenberg Eric","position":1,"cik":"0001646300","reported_name":"Trachtenberg Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T16:07:04.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":20500,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001415889-24-000772","document":"form4-01052024_090146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1646300/000141588924000772/form4-01052024_090146.xml","form_type":"4"}},{"id":1685476,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":95409,"kind":"person","name":"Trachtenberg Eric","position":1,"cik":"0001646300","reported_name":"Trachtenberg Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-01-05T16:07:04.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1227,"price":6.74,"value":8269.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 64,149 unvested RSUs."}],"balance_after":68066,"source":{"system":"sec-edgar","filing":"0001415889-24-000772","document":"form4-01052024_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1646300/000141588924000772/form4-01052024_090146.xml","form_type":"4"}},{"id":1685475,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":95409,"kind":"person","name":"Trachtenberg Eric","position":1,"cik":"0001646300","reported_name":"Trachtenberg Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2024-01-05T16:07:04.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 67,474 unvested RSUs."}],"balance_after":69293,"source":{"system":"sec-edgar","filing":"0001415889-24-000772","document":"form4-01052024_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1646300/000141588924000772/form4-01052024_090146.xml","form_type":"4"}},{"id":1685540,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T16:04:02.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":20500,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001415889-24-000767","document":"form4-01052024_090154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924000767/form4-01052024_090154.xml","form_type":"4"}},{"id":1685539,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T16:04:02.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1227,"price":6.74,"value":8269.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 61,831 unvested RSUs."}],"balance_after":66136,"source":{"system":"sec-edgar","filing":"0001415889-24-000767","document":"form4-01052024_090154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924000767/form4-01052024_090154.xml","form_type":"4"}},{"id":1685538,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T16:04:02.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 65,156 unvested RSUs."}],"balance_after":67363,"source":{"system":"sec-edgar","filing":"0001415889-24-000767","document":"form4-01052024_090154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924000767/form4-01052024_090154.xml","form_type":"4"}},{"id":1845155,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:35.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023."}],"balance_after":2500,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-23-010292","document":"form4-06232023_080626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010292/form4-06232023_080626.xml","form_type":"4"}},{"id":1845154,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:35.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":4922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":4922,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":4922},"source":{"system":"sec-edgar","filing":"0001415889-23-010292","document":"form4-06232023_080626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010292/form4-06232023_080626.xml","form_type":"4"}},{"id":1845153,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-24T00:00:35.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 6,392 unvested RSUs."}],"balance_after":6392,"source":{"system":"sec-edgar","filing":"0001415889-23-010292","document":"form4-06232023_080626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010292/form4-06232023_080626.xml","form_type":"4"}},{"id":1845152,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":78385,"kind":"person","name":"Farid Marjan","position":1,"cik":"0001952098","reported_name":"Farid Marjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-24T00:00:35.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":3692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,292 unvested RSUs."}],"balance_after":5292,"source":{"system":"sec-edgar","filing":"0001415889-23-010292","document":"form4-06232023_080626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010292/form4-06232023_080626.xml","form_type":"4"}},{"id":1845159,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":40433,"kind":"person","name":"KOVEN ANDREW I","position":1,"cik":"0001258673","reported_name":"KOVEN ANDREW I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:33.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023."}],"balance_after":3150,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001415889-23-010288","document":"form4-06232023_080619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010288/form4-06232023_080619.xml","form_type":"4"}},{"id":1845158,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":40433,"kind":"person","name":"KOVEN ANDREW I","position":1,"cik":"0001258673","reported_name":"KOVEN ANDREW I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:33.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":10020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":10020,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":10020},"source":{"system":"sec-edgar","filing":"0001415889-23-010288","document":"form4-06232023_080619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010288/form4-06232023_080619.xml","form_type":"4"}}],"next_cursor":"2023-06-24T00:00:33.000000Z,1845158"}